XML 26 R77.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions - Additional Information (Details) (USD $)	3 Months Ended		1 Months Ended		33 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Dec. 07, 2014	Sep. 30, 2013	Nov. 20, 2013	Sep. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Compensation expense	$ 0xon_ContributionOfServicesByShareholder	$ 470,000xon_ContributionOfServicesByShareholder
Payments to acquire other investments	14,900,000us-gaap_PaymentsToAcquireOtherInvestments	0us-gaap_PaymentsToAcquireOtherInvestments
Assets, Fair Value Disclosure	387,188,000us-gaap_AssetsFairValueDisclosure		387,188,000us-gaap_AssetsFairValueDisclosure							280,497,000us-gaap_AssetsFairValueDisclosure
Collaboration revenue	14,735,000xon_CollaborationRevenues	7,837,000xon_CollaborationRevenues
Third Security
Related Party Transaction [Line Items]
Total amount of expenses reimbursed	41,000us-gaap_ProfessionalAndContractServicesExpense / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ThirdSecurityMember	24,000us-gaap_ProfessionalAndContractServicesExpense / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ThirdSecurityMember
Chief Executive Officer
Related Party Transaction [Line Items]
Compensation expense		470,000xon_ContributionOfServicesByShareholder / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap_ChiefExecutiveOfficerMember
AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Shares of common stock purchased from collaborative partners			13,939,392xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
Warrants purchased from collaborative partners			3,484,848xon_WarrantsPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
Payments to acquire other investments			2,300,000us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Common stock purchase commitment	50,000,000xon_AdditionalSharesValueAgreedToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember		50,000,000xon_AdditionalSharesValueAgreedToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember
Shares of common stock purchased from collaborative partners				12,600,000xon_SharesPurchasedFromCollaborativePartnersValue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember	30,982,000xon_SharesPurchasedFromCollaborativePartnersValue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_ZiopharmMember
Histogenics Corporation
Related Party Transaction [Line Items]
Shares of common stock purchased from collaborative partners						1,772,364xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember
Note receivable, stated interest rate									6.00%xon_NoteReceivableInterestRate / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember
Price per share of common shares						$ 11.00xon_SharesPurchasedPricePerShare / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember
Oragenics, Inc.
Related Party Transaction [Line Items]
Shares of common stock purchased from collaborative partners							1,300,000xon_SharesPurchasedFromCollaborativePartners / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember
Price per share of common shares									$ 3.00xon_SharesPurchasedPricePerShare / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember
Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase	30.00%xon_MaximumPercentageOfSharesEntitledToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember		30.00%xon_MaximumPercentageOfSharesEntitledToPurchase / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember
Oragenics, Inc. | Share Purchase Rights Plan
Related Party Transaction [Line Items]
Shares of common stock purchased from collaborative partners								1,100,000xon_SharesPurchasedFromCollaborativePartners / invest_InvestmentAxis = xon_SharePurchaseRightsPlanMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember
Price per share of common shares								$ 2.50xon_SharesPurchasedPricePerShare / invest_InvestmentAxis = xon_SharePurchaseRightsPlanMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_OragenicsMember
Related Parties, Aggregated
Related Party Transaction [Line Items]
Collaboration revenue	12,796,000xon_CollaborationRevenues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_RelatedPartiesAggregatedMember	7,398,000xon_CollaborationRevenues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_RelatedPartiesAggregatedMember
Common Stock | AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Payments to acquire other investments			1,979,000us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_InvestmentTypeAxis = us-gaap_CommonStockMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
Warrants | AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Payments to acquire other investments			321,000us-gaap_PaymentsToAcquireOtherInvestments / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
Assets, Fair Value Disclosure	756,000us-gaap_AssetsFairValueDisclosure / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember		756,000us-gaap_AssetsFairValueDisclosure / us-gaap_InvestmentTypeAxis = us-gaap_WarrantMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_AmpliPhiBiosciencesCorpMember
Upfront and Milestone Payments
Related Party Transaction [Line Items]
Collaboration revenue	3,031,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember	1,882,000xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember
Upfront and Milestone Payments | Upfront | Histogenics Corporation
Related Party Transaction [Line Items]
Collaborative arrangement consideration received, value of convertible promissory note									$ 10,000,000xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xon_HistogenicsCorporationMember

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name:	us-gaap_AssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The cash outflow associated with other investments held by the entity for investment purposes not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.

+ References

No definition available.

+ Details

Name:	us-gaap_ProfessionalAndContractServicesExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Value of additional common stock for which the entity has committed to purchasing from collaborator, original

+ References

No definition available.

+ Details

Name:	xon_AdditionalSharesValueAgreedToPurchase
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration agreements.

+ References

No definition available.

+ Details

Name:	xon_CollaborationRevenues
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock.

+ References

No definition available.

+ Details

Name:	xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Compensation expense recognized for value of services contributed by a shareholder

+ References

No definition available.

+ Details

Name:	xon_ContributionOfServicesByShareholder
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Percentage of shares that the entity is entitled to purchase in securities offerings conducted by collaborator, maximum.

+ References

No definition available.

+ Details

Name:	xon_MaximumPercentageOfSharesEntitledToPurchase
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Interest rate per annum of the note receivable.

+ References

No definition available.

+ Details

Name:	xon_NoteReceivableInterestRate
Namespace Prefix:	xon_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of shares of common stock purchased from collaborator

+ References

No definition available.

+ Details

Name:	xon_SharesPurchasedFromCollaborativePartners
Namespace Prefix:	xon_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Value of common stock purchased from collaborator

+ References

No definition available.

+ Details

Name:	xon_SharesPurchasedFromCollaborativePartnersValue
Namespace Prefix:	xon_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Price per share of collaborator's common stock purchased

+ References

No definition available.

+ Details

Name:	xon_SharesPurchasedPricePerShare
Namespace Prefix:	xon_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of warrants purchased from collaborator

+ References

No definition available.

+ Details

Name:	xon_WarrantsPurchasedFromCollaborativePartners
Namespace Prefix:	xon_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_AmpliPhiBiosciencesCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_HistogenicsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_OragenicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_RelatedPartiesAggregatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ThirdSecurityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ZiopharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: